Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts

Loading news article.

Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts | WAPE

Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts

Article summary

Related companies

Comments —